8-K: CalciMedica Announces FDA Clearance for Phase 2 Trial of Auxora in Acute Kidney Injury and Provides Pipeline Updates

CalciMedica has received FDA clearance for a Phase 2 trial of Auxora in acute kidney injury and anticipates data readouts for multiple trials in 2024 and 2025.

Summary

• CalciMedica announced the FDA clearance of its Investigational New Drug application for Auxora to be evaluated in a Phase 2 trial for acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
• The Phase 2 trial, named KOURAGE, is expected to begin in the first half of 2024, with data expected in 2025.
• The KOURAGE trial will enroll 150 patients with stage 2 and 3 AKI who have AHRF and are receiving oxygen by non-invasive mechanical ventilation, high flow nasal cannula or intermittent mandatory ventilation.
• The primary endpoint of the trial will be evaluation of patients through day 30 to determine days alive, ventilator-free and dialysis-free.
• Secondary endpoints will include a composite of all-cause mortality, decrease in estimated glomerular filtration rate (eGFR), and the incidence of dialysis over a period of 90 days.
• The company also provided updates on its pipeline, including data readouts expected in the first half of 2024 for the Phase 2b CARPO trial in acute pancreatitis and a Phase 2 biomarker trial in mechanically ventilated COVID-19 patients.
• Data is expected in the second half of 2024 for the investigator-sponsored Phase 1/2 CRSPA trial in pediatric patients with asparaginase-induced pancreatic toxicity.
• CalciMedica plans to submit IND applications to the FDA in the second half of 2024 for its oral candidate CM6336 for the treatment of chronic pancreatitis and rheumatoid arthritis.
• Following a recent private placement, the company expects to have a cash runway into the second half of 2025.

Sentiment

Score: 7

Explanation: The document is positive due to the FDA clearance and multiple upcoming data readouts, but there are inherent risks associated with clinical trials and regulatory approvals.

Positives

• FDA clearance of the IND application for Auxora in AKI is a significant regulatory milestone.
• The KOURAGE trial has a well-defined primary endpoint focused on patient outcomes.
• The company has multiple data readouts expected in 2024, providing several potential catalysts.
• The company has a diversified pipeline with both intravenous and oral candidates.
• The company has secured funding to extend its cash runway into the second half of 2025.

Negatives

• The company is still in the clinical trial phase, and there is no guarantee of positive results.
• The company is reliant on successful clinical trials and regulatory approvals.
• The company is operating in a competitive market with other companies developing therapies for similar indications.

Risks

• Clinical trial results may not be positive or may not be indicative of future results.
• Regulatory approvals may not be granted or may be delayed.
• The company may face challenges in commercializing its products.
• The company may face competition from other companies developing similar therapies.
• The company's cash runway is dependent on successful fundraising and may not be sufficient to complete all planned activities.

Future Outlook

The company anticipates multiple data readouts from ongoing clinical trials in 2024 and 2025, and plans to submit IND applications for its oral candidate CM6336 in the second half of 2024. The company expects to have a cash runway into the second half of 2025.

Management Comments

• The company may use the corporate presentation from time to time in conversations with analysts, investors and others.

Industry Context

The announcement is relevant to the pharmaceutical and biotechnology industries, particularly companies focused on developing therapies for inflammatory and immunologic diseases. The focus on acute kidney injury and acute pancreatitis addresses significant unmet medical needs. The company is competing with other companies developing therapies for similar indications.

Comparison to Industry Standards

• CalciMedica's approach of targeting CRAC channels is a novel approach in the treatment of inflammatory diseases, differentiating it from companies using more traditional methods.
• The company's focus on both intravenous and oral formulations allows for a broader range of applications, similar to companies like Vertex Pharmaceuticals that have both acute and chronic treatments.
• The company's clinical trial designs, such as the KOURAGE trial with its focus on patient-centric endpoints, are in line with industry best practices.
• The company's timeline for data readouts and IND submissions is comparable to other biotech companies in similar stages of development, such as Kiniksa Pharmaceuticals and InflaRx.

Stakeholder Impact

• Shareholders may see a positive impact from the FDA clearance and upcoming data readouts.
• Patients with AKI, acute pancreatitis, and other inflammatory diseases may benefit from the development of new therapies.
• Employees may be impacted by the company's progress and future growth.
• Creditors may be impacted by the company's financial performance and cash runway.

Next Steps

• Initiate the Phase 2 KOURAGE trial in the first half of 2024.
• Present pre-clinical study results at the 29th International AKI & Continuous Renal Replacement Therapy Conference in March 2024.
• Release data from the Phase 2b CARPO trial in the first half of 2024.
• Release data from the Phase 1/2 CRSPA trial in the second half of 2024.
• Submit IND applications for CM6336 in the second half of 2024.
• Release data from the KOURAGE trial in 2025.

Key Dates

Keywords

Auxora, Acute Kidney Injury, AKI, Acute Pancreatitis, AHRF, CRAC channels, Clinical Trial, FDA, CM6336, CARPO, CRSPA, KOURAGE, Biomarker, COVID-19, ARDS, Rheumatoid Arthritis, Chronic Pancreatitis